Tyrosine kinase inhibitors (TKIs) serve as first-line treatments for advanced hepatocellular carcinoma, obstructing tumor angiogenesis by blocking signaling pathways such as vascular endothelial growth factor (VEGF) (12, 13). This evidence concerns the gene VEGFA and hepatocellular carcinoma.